The US Food and Drug Administration and National Institutes of Health are working together on two separate projects that aim to advance novel treatments, the FDA has recently announced.
The first project, the Critical Path for Rare Neurodegenerative Diseases (CP-RND), is a public-private partnership to develop better understanding...